m6A regulator expression profile predicts the prognosis, benefit of adjuvant chemotherapy, and response to anti-PD-1 immunotherapy in patients with small-cell lung cancer

Zhihui Zhang,Chaoqi Zhang,Yuejun Luo,Peng Wu,Guochao Zhang,Qingpeng Zeng,Lide Wang,Zhaoyang Yang,Liyan Xue,Bo Zheng,Hua Zeng,Fengwei Tan,Qi Xue,Shugeng Gao,Nan Sun,Jie He
DOI: https://doi.org/10.1186/s12916-021-02148-5
IF: 9.3
2021-11-22
BMC Medicine
Abstract:Abstract Background Small cell lung cancer (SCLC) is lethal and possesses limited therapeutic options. Platinum-based chemotherapy—with or without immune checkpoint inhibitors (anti-PDs)—is the current first-line therapy for SCLCs; however, its associated outcomes are heterogeneous. N 6 -methyladenosine (m 6 A) is a novel and decisive factor in tumour progression, chemotherapy resistance, and immunotherapy response. However, m 6 A modification in SCLC remains poorly understood. Methods We systematically explored the molecular features and clinical significance of m 6 A regulators in SCLC. We then constructed an m 6 A regulator-based prognostic signature (m 6 A score) based on our examination of 256 cases with limited-stage SCLC (LS-SCLC) from three different cohorts—including an independent cohort that contained 150 cases with qPCR data. We additionally evaluated the relationships between the m 6 A score and adjuvant chemotherapy (ACT) benefits and the patients’ responses to anti-PD-1 treatment. Immunohistochemical (IHC) staining and the HALO digital pathological platform were used to calculate CD8+ T cell density. Results We observed abnormal somatic mutations and expressions of m 6 A regulators. Using the LASSO Cox model, a five-regulator-based ( G3BP1 , METTL5 , ALKBH5 , IGF2BP3 , and RBM15B ) m 6 A score was generated from the significant regulators to classify patients into high- and low-score groups. In the training cohort, patients with high scores had shorter overall survival (HR, 5.19; 2.75–9.77; P < 0.001). The prognostic accuracy of the m 6 A score was well validated in two independent cohorts (HR 4.6, P = 0.006 and HR 3.07, P < 0.001). Time-dependent ROC and C-index analyses found the m 6 A score to possess superior predictive power than other clinicopathological parameters. A multicentre multivariate analysis revealed the m 6 A score to be an independent prognostic indicator. Additionally, patients with low scores received a greater survival benefit from ACT, exhibited more CD8+ T cell infiltration, and were more responsive to cancer immunotherapy. Conclusions Our results, for the first time, affirm the significance of m 6 A regulators in LS-SCLC. Our multicentre analysis found that the m 6 A score was a reliable prognostic tool for guiding chemotherapy and immunotherapy selections for patients with SCLC.
medicine, general & internal
What problem does this paper attempt to address?